-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
After leaving Tengsheng Bo Medicine, where is Luo Yongqing's next stop? This question finally has an answer
On 19 September 2022, Genting New Yao announced the appointment of Luo Yongqing as the Chief Executive Officer of the Company, with immediate effect
Luo Yongqing's joining Genting Xinyao seems to have been foreshadowed
Shortly before Luo Yongqing left Tengshengbo Pharmaceutical, Genting Xinyao announced that CEO Bo Kerui had resigned as an executive director and chief executive officer of the company due to personal affairs, effective
In Genting New Yao's announcement today, Fu Wei, Chairman of Genting New Yao and Chief Executive Officer of Kangqiao Capital, said: "In the future, we will strive to make the main candidates in the late stage of clinical development, including Nefecon, Xerava, etrasimod and mRNA vaccine market approved, under the leadership of Mr.
Luo Yongqing also said: "We will continue to promote the development of late-stage product pipelines for commercialization, and plan to use our strong cash flow to facilitate business expansion and accelerate the development into an integrated biopharmaceutical company
Incubated by Kangqiao Capital, Genting New Yao was founded in 2017 under the License-in model and successfully listed
Among them, the antibiotic Xerava™ (ellacycline), which treats complicated intra-abdominal infection (cIAI), has been submitted to the NMPA in March 2021 and has not yet been approved
It is worth noting that Genting Xinyao focuses on the layout of new crown vaccines and drugs
In addition, it has also introduced a set of 3CL protease inhibitors from the Singapore Experimental Drug Development Center (EDDC) as a globally exclusive licensed drug EDDC-2214 for the treatment of COVID-19
Genting New Yao expects Xerava, Nefecon and PTX-COVID19-B products to be available
At present, Genting Xinyao has set up a commercialization team, and Luo Yongqing's addition is believed to be based on his successful experience in leading the successful
As of today's close, Genting Xinyao shares fell 5.
